DNA methylation level is marker of breast cancer risk

May 11, 2012
DNA methylation level is marker of breast cancer risk

(HealthDay) -- Women with high levels of white blood cell (WBC) DNA methylation at the ATM loci have a significantly increased risk of breast cancer, regardless of family history or menopausal status, according a study published in the May 1 issue of Cancer Research.

Kevin Brennan, of Imperial College in London, and colleagues evaluated WBC as a biomarker of using prediagnostic blood samples from three cohorts. DNA methylation at two ATM intragenic loci, ATMmvp2a and ATMmvp2b, and genome-wide methylation of long interspersed nuclear element-1 (LINE1) repetitive elements were analyzed. Methylation was quantified in 640 incident cases of and 741 controls.

The researchers found that patients with WBC DNA methylation at the ATMmvp2a loci in the highest quintile had a significantly increased risk of breast cancer (odds ratio, 1.89), irrespective of family history or menopausal status. This relationship was more consistently observed in women under the age of 60 years compared with older women, and was significant in two of the cohorts. There was no difference between cases and controls in methylation of ATMmvp2b or LINE1.

"In conclusion, our findings on the association between ATM hypermethylation in WBC DNA before diagnosis and the risk of developing breast cancer provide further support for the investigation of common epigenetic variability as risk markers for breast and other cancers," the authors write.

Explore further: Breast cancer risk can be seen years before it develops

More information: Abstract
Full Text

Related Stories

Breast cancer risk can be seen years before it develops

May 2, 2012
A person’s risk of breast cancer could be decided many years before it develops, according to a new study.

Maternal glycemic status linked to epigenetic changes

March 9, 2012
(HealthDay) -- Maternal glycemic status and adiponectin levels are linked to epigenetic changes in the adiponectin gene (ADIPOQ), according to a study published online March 6 in Diabetes.

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.